TABLE 1.
Patient demographics
| Characteristic | TNS grade 0 (0–1) | TNS grade 1 (2–8) | TNS grade 2 (9–16) | TNS grade 3 (17–24) | p | Entire cohort |
|---|---|---|---|---|---|---|
| n | 31 | 78 | 36 | 11 | 156 | |
| Age, years | 55.84 ± 2.38 | 66.15 ± 1.25 | 66.56 ± 2.40 | 71.45 ± 3.88 | <0.001 | 64.57 ± 1.05 |
| Men/women | 19/12 | 36/42 | 30/6 | 8/3 | 0.001 | 93/63 |
| BMI, kg/m2 | 31.02 ± 1.20 | 32.35 ± 0.75 | 31.62 ± 1.39 | 33.01 ± 1.82 | 0.769 | 32.0 ± 0.6 |
| Waist circumference, cm | 104.47 ± 2.76 | 108.20 ± 1.71 | 113.16 ± 3.22 | 106.73 ± 11.40 | 0.265 | 108.55 ± 1.48 |
| Disease duration, months | 127.23 ± 14.90 | 176.31 ± 16.03 | 198.83 ± 20.73 | 259.63 ± 49.14 | 0.020 | 177.64 ± 10.61 |
| TNS | 0.2 ± 0.1 | 4.5 ± 0.3 | 11.9 ± 0.4 | 19.1 ± 0.4 | <0.001 | 6.4 ± 0.5 |
| mTCNS | 0.3 ± 0.1 | 4.4 ± 0.3 | 12.0 ± 0.6 | 20.5 ± 1.7 | <0.001 | 6.5 ± 0.5 |
| HbA1c, % | 8.1 ± 0.3 | 8.1 ± 0.2 | 8.5 ± 0.3 | 9.4 ± 0.6 | 0.092 | 8.3 ± 0.1 |
| HbA1c, IFCC units | 65 ± 3 | 65 ± 2 | 69 ± 3 | 79 ± 6 | 67 ± 1 | |
| eGFR, ml/min/1.73 m2 | 72.7 ± 4.0 | 71.2 ± 2.6 | 68.2 ± 4.1 | 64.4 ± 5.9 | 0.675 | 70.3 ± 1.8 |
| Potassium, mmol/L | 4.3 ± 0.1 | 4.5 ± 0.1 | 4.5 ± 0.1 | 4.4 ± 0.1 | 0.353 | 4.4 ± 0.03 |
| Sural SNAP, μV | 13.0 ± 1.1 | 8.1 ± 1.0 | 2.1 ± 0.5 | 0 | <0.001 | 7.1 ± 0.6 |
| Tibial CMAP, mV | 9.4 ± 0.7 | 7.7 ± 0.6 | 3.8 ± 0.5 | 0.8 ± 0.4 | <0.001 | 6.6 ± 0.4 |
Note: Figures are quoted as mean ± SE. Probability values are denoted for analysis of variance of mean between groups.
Abbreviations: BMI, body mass index; CMAP, compound muscle action potential; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; IFCC, International Federation of Clinical Chemistry; mTCNS, modified Toronto Clinical Neuropathy Scale; SNAP, sensory nerve action potential; TNS, Total Neuropathy Score.